drugset
drugset / Trial / NCT01338415

FUTURE 3 Study Extension

NCT01338415 ↗

Phase 3 Completed 58 enrolled Actelion
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The objectives of the FUTURE 3 Study Extension are to evaluate the long-term safety, tolerability and efficacy of the pediatric formulation of bosentan two versus three times a day in children with Pulmonary Arterial Hypertension (PAH).

Timeline

Start
2011-03-08
Primary completion
2014-08-13
Completion
2020-05-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Bosentan Other / unclassified 2 mg/kg Oral

Indications

pulmonary arterial hypertension